<DOC>
	<DOCNO>NCT02064166</DOCNO>
	<brief_summary>Parkinson disease ( PD ) multiple system atrophy ( MSA ) progressive neurodegenerative disorder characterize abnormal accumulation Î±-synuclein . There effective treatment slow disease progression disorder associate severe cognitive decline . It show intranasal insulin ( INI ) improve learn memory healthy cognitively impaired non-diabetic adult . The proof-of-concept , randomize , placebo-controlled , cross-over pilot study ( NCT01206322 ) show single 40 international unit dose intranasal insulin improve visuospatial memory diabetes control subject . This proposal include randomize , double blind , placebo-controlled trial intranasal insulin ( 40 international unit daily ) treatment PD MSA . The study evaluate 22 patient PD 22 patient MSA . Total duration study 2 year . The primary goal ass efficacy INI treatment cognitive abnormality PD MSA . The primary efficacy end point change cognitive scale rating .</brief_summary>
	<brief_title>Treatment Parkinson Disease Multiple System Atrophy Using Intranasal Insulin .</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Males females old 17 year . 2 . Clinical diagnosis Parkinson disease multiple system atrophy . 3 . Provide write informed consent participate study . 4 . Understand may withdraw consent time . 1 . Women pregnant lactating . 2 . In investigator 's opinion , significant systemic , hepatic , cardiovascular , renal illness interfere base investigator judgment trial . 3 . History dementia . 4 . Unable walk without help least 1 minute . 5 . History allergic reaction insulin . 6 . The presence inflammation nasal cavity may prevent absorption insulin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Parkinson disease</keyword>
	<keyword>Multiple system atrophy</keyword>
	<keyword>Intranasal</keyword>
	<keyword>Insulin</keyword>
</DOC>